Header Logo

Connection

MEENAKSHI ANURAG to Female

Back to Details
This is a "connection" page, showing publications MEENAKSHI ANURAG has written about Female.
MEENAKSHI ANURAG
Connection Strength
0.256
Female
  1. How valuable can proteogenomics be in clinical breast cancer research? Expert Rev Proteomics. 2023 Jan-Mar; 20(1-3):1-4.
    View in: PubMed
    Score: 0.033
  2. Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance). J Natl Cancer Inst. 2020 07 01; 112(7):737-746.
    View in: PubMed
    Score: 0.027
  3. CDK4/6 Inhibitor Biomarker Research: Are We Barking Up the Wrong Tree? Clin Cancer Res. 2020 01 01; 26(1):3-5.
    View in: PubMed
    Score: 0.026
  4. Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers. Clin Cancer Res. 2018 10 01; 24(19):4887-4899.
    View in: PubMed
    Score: 0.024
  5. PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 01; 23(10):1494-1510.
    View in: PubMed
    Score: 0.009
  6. Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 Mar 01; 10(3):362-371.
    View in: PubMed
    Score: 0.009
  7. The Breast Cancer Proteome and Precision Oncology. Cold Spring Harb Perspect Med. 2023 10 03; 13(10).
    View in: PubMed
    Score: 0.009
  8. Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer. Cancer Res. 2023 10 02; 83(19):3237-3251.
    View in: PubMed
    Score: 0.009
  9. Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment. Cancer Res Commun. 2023 07; 3(7):1366-1377.
    View in: PubMed
    Score: 0.008
  10. Elevated NRAS expression during DCIS is a potential driver for progression to basal-like properties and local invasiveness. Breast Cancer Res. 2022 10 18; 24(1):68.
    View in: PubMed
    Score: 0.008
  11. Poziotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer. Cancer Res. 2022 08 16; 82(16):2928-2939.
    View in: PubMed
    Score: 0.008
  12. Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031). Clin Cancer Res. 2022 08 02; 28(15):3287-3295.
    View in: PubMed
    Score: 0.008
  13. Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer. Cancer Res. 2021 12 15; 81(24):6259-6272.
    View in: PubMed
    Score: 0.008
  14. Immunogenomic?profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer. Breast Cancer Res Treat. 2021 Aug; 189(1):187-202.
    View in: PubMed
    Score: 0.007
  15. Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. Cancer Cell. 2021 03 08; 39(3):361-379.e16.
    View in: PubMed
    Score: 0.007
  16. Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy. Cell. 2020 11 25; 183(5):1436-1456.e31.
    View in: PubMed
    Score: 0.007
  17. Neurofibromin Is an Estrogen Receptor-a Transcriptional Co-repressor in Breast Cancer. Cancer Cell. 2020 03 16; 37(3):387-402.e7.
    View in: PubMed
    Score: 0.007
  18. Endocrine therapy resistance: new insights. Breast. 2019 Nov; 48 Suppl 1:S26-S30.
    View in: PubMed
    Score: 0.007
  19. Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort. Breast Cancer Res Treat. 2020 Jan; 179(1):3-10.
    View in: PubMed
    Score: 0.006
  20. Copy number alterations associated with clinical features in an underrepresented population with breast cancer. Mol Genet Genomic Med. 2019 07; 7(7):e00750.
    View in: PubMed
    Score: 0.006
  21. The prognostic effects of somatic mutations in ER-positive breast cancer. Nat Commun. 2018 09 04; 9(1):3476.
    View in: PubMed
    Score: 0.006
  22. Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Rep. 2018 08 07; 24(6):1434-1444.e7.
    View in: PubMed
    Score: 0.006
  23. Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer. Cancer Discov. 2017 10; 7(10):1168-1183.
    View in: PubMed
    Score: 0.006
  24. Amplification of TLK2 Induces Genomic Instability via Impairing the G2-M Checkpoint. Mol Cancer Res. 2016 10; 14(10):920-927.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.